{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T01:13:25Z","timestamp":1768871605450,"version":"3.49.0"},"reference-count":55,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2020,6,24]],"date-time":"2020-06-24T00:00:00Z","timestamp":1592956800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Brit J Clinical Pharma"],"published-print":{"date-parts":[[2020,10]]},"abstract":"<jats:sec><jats:title>Aims<\/jats:title><jats:p>Medication safety requires urgent attention in hospital pharmacy. This study evaluated the medication\u2010related problems\/errors as reported to the Dutch medication incident registry and disseminated for information to pharmacists. Through analysis by an expert panel we aimed to better understand which problems could have been mitigated by the drug product design. Additionally, the (wider) implications of the problems for current hospital\/clinical practice were discussed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Items were extracted from the public Portal for Patient Safety. Items were included if relevant for older people and connected with the drug product design and excluded if they should reasonably have been intercepted by compliance to routine controls or well\u2010known professional standards in pharmaceutical care. To explore any underreporting of well\u2010known incidents, it was investigated if different medication\u2010related problems could be observed in a regional hospital practise over a 1\u2010month period. For 6 included items (cases), the implications for hospital\/clinical practise were discussed in an expert panel.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 307 items were identified in the Portal for Patient Safety; all but 14 were excluded. Six cases were added from daily hospital practice. These 20 cases commonly related to confusing product characteristics, packaging issues such as the lack of a single unit package for an oncolytic product, or incorrect or incomplete user instructions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Medication registries provide important opportunities to evaluate real\u2010world medication\u2010related problems. However, underreporting of well\u2010known problems should be considered. The product design can be used as an (additional) risk mitigation measure to support medication safety in hospital practice.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bcp.14392","type":"journal-article","created":{"date-parts":[[2020,5,30]],"date-time":"2020-05-30T18:00:29Z","timestamp":1590861629000},"page":"1946-1957","source":"Crossref","is-referenced-by-count":10,"title":["Opportunities for changes in the drug product design to enhance medication safety in older people: Evaluation of a national public portal for medication incidents"],"prefix":"10.1111","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3077-9663","authenticated-orcid":false,"given":"Fatma","family":"Karapinar\u2010\u00c7arkit","sequence":"first","affiliation":[{"name":"Department of Clinical Pharmacy OLVG hospital  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1418-5520","authenticated-orcid":false,"given":"Patricia M.L.A.","family":"van den Bemt","sequence":"additional","affiliation":[{"name":"Department of Hospital Pharmacy University Medical Center Groningen  Groningen The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariam","family":"Sadik","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy OLVG hospital  Amsterdam The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigit","family":"van Soest","sequence":"additional","affiliation":[{"name":"Royal Pharmaceutical Society in the Netherlands (KNMP)  The Hague The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wilma","family":"Knol","sequence":"additional","affiliation":[{"name":"Department of Geriatric Medicine and Expertise Centre Pharmacotherapy in Old Persons (EPHOR) University Medical Centre Utrecht  The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Florence","family":"van Hunsel","sequence":"additional","affiliation":[{"name":"Netherlands Pharmacovigilance Centre Lareb, \u2018s Hertogenbosch  The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4902-4519","authenticated-orcid":false,"given":"Diana A.","family":"van Riet\u2010Nales","sequence":"additional","affiliation":[{"name":"Medicines Evaluation Board  Utrecht The Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2020,6,24]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1002\/msj.20278"},{"key":"e_1_2_9_3_1","first-page":"1","article-title":"Prescribing medicines to older people \u2010 how to consider the impact of ageing on human organ and body functions","author":"Drenth\u2010van Maanen ACC","year":"2019","journal-title":"Br J Clin Pharmacol"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1532-5415.2012.04121.x"},{"key":"e_1_2_9_5_1","unstructured":"VMS.VMS veiligheidsprogramma kwetsbare ouderen. Available athttps:\/\/www.vmszorg.nl\/vms-veiligheidsprogramma\/10-themas\/. Accessed 21 April 2020."},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00516-4"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMp1209034"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0213593"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.15244"},{"issue":"8","key":"e_1_2_9_10_1","first-page":"614","article-title":"Ntifying the optimal role for pharmacists in care transitions: a systematic review","volume":"21","author":"Ensing HT","year":"2015","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0b013e3182a977da"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12603-013-0359-2"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1111\/jgs.13126"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0361-1"},{"key":"e_1_2_9_15_1","unstructured":"Pharmaceutical Care Network Europe.Classification for Drug related problems: The PCNE Classification version 6.2. Available athttps:\/\/www.pcne.org\/upload\/files\/11_PCNE_classification_V6-2.pdf2016;Accessed 22 April 2020."},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-010-0007-8"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/fampra\/cms070"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-43896-2_6"},{"issue":"1","key":"e_1_2_9_19_1","first-page":"230","article-title":"A nationwide medication incidents reporting system in the Netherlands","volume":"23","author":"Cheung KC","year":"2016","journal-title":"Corrigendum to: J Am Med Inform Assoc"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(14)60603-6"},{"key":"e_1_2_9_21_1","unstructured":"Portal for Patient Safety. Overleg met CBG. Available athttps:\/\/www.vim-digitaal.nl\/pages\/125\/Informatie-aanvragen_html. Accessed 27 November 2019."},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jmir.2009.06.002"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0101686"},{"issue":"1","key":"e_1_2_9_24_1","first-page":"e63","article-title":"Classification of medication incidents associated with information technology","volume":"21","author":"Cheung KC","year":"2014","journal-title":"JAMA"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/intqhc\/mzy177"},{"key":"e_1_2_9_26_1","unstructured":"European MEdicines Agency (EMA).Pharmacovigilance Risk Assessment Committee (PRAC). Good Practice Guide on risk minimisation and prevention of medication errors. Available athttps:\/\/www.emae.uropa.eu\/en\/documents\/regulatory-procedural-guideline\/good-practice-guide-risk-minimisation-prevention-medication-errors_en.pdf. 2015;Accessed 1 February 2020."},{"key":"e_1_2_9_27_1","unstructured":"European MEdicines Agency (EMA).Committee for Human Medicinal Products (CHMP). Reflection paper on the pharmaceutical development of medicines for use in the older population (draft). Available athttps:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-pharmaceutical-development-medicines-use-older-population-first-version_en.pdf. 2017;Accessed 28 October 2019."},{"key":"e_1_2_9_28_1","unstructured":"European Medicines Agency (EMA).Committee for Human Medicinal Products (CHMP) and the EMA Paediatric Committee (PDCO). Guideline on pharmaceutical development of medicines for paediatric use. Available athttps:\/\/www.ema.europaeu\/en\/documents\/scientific-guideline\/guideline-pharmaceutical-development-medicines-paediatric-use_en.pdf. 2013;Accessed 27 October 2019."},{"key":"e_1_2_9_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pec.2010.05.020"},{"key":"e_1_2_9_30_1","unstructured":"Farmacotherapeutisch Kompas.Tramadol. Available athttps:\/\/www.farmacotherapeutischkompas.nl\/bladeren\/preparaatteksten\/t\/tramadol#doseringce.2019. Accessed 27 October 2019."},{"issue":"5","key":"e_1_2_9_31_1","first-page":"1","article-title":"Pharmaceutical regulation in 15 European countries review","volume":"18","author":"Panteli D","year":"2016","journal-title":"Health Sys Transit"},{"key":"e_1_2_9_32_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2016.05.001"},{"key":"e_1_2_9_33_1","unstructured":"MSD Nederland BV.DHPC Posaconazol. Available athttps:\/\/www.cbg-mebnl\/\u203a actueel \u203a nieuws \u203a 2016\/08\/24 \u203a dhpc\u2010noxafil. 2016;Accessed 27 October 2019."},{"key":"e_1_2_9_34_1","doi-asserted-by":"publisher","DOI":"10.1136\/ejhpharm-2017-001224"},{"issue":"1","key":"e_1_2_9_35_1","first-page":"16","article-title":"Stability of dabigatran Etexilate in Manufacturer's blister pack, unit\u2010dose packaging, and community pharmacy blister pack","volume":"68","author":"Wang EH","year":"2015","journal-title":"Can J Hosp Pharm"},{"key":"e_1_2_9_36_1","unstructured":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use. ICH tripartite guideline Quality Risk Management Q9. available at:https:\/\/database.ich.org\/sites\/default\/files\/Q9%20Guideline.pdf2005;Accessed 1 February 2020."},{"key":"e_1_2_9_37_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-013-9757-0"},{"key":"e_1_2_9_38_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13181-015-0471-2"},{"key":"e_1_2_9_39_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2016.03.007"},{"key":"e_1_2_9_40_1","doi-asserted-by":"publisher","DOI":"10.1331\/1544-3191.44.5.583.Brotherman"},{"key":"e_1_2_9_41_1","first-page":"1","article-title":"The package barrier to user adherence: comparative analysis of various types of opening instructions on the ease of opening comprising effectiveness, efficiency and user satisfaction","volume":"10","author":"Braun\u2010Munker M","year":"2019","journal-title":"Br J Clin Pharm"},{"key":"e_1_2_9_42_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11096-012-9643-1"},{"key":"e_1_2_9_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2010.04.005"},{"key":"e_1_2_9_44_1","doi-asserted-by":"publisher","DOI":"10.4178\/epih.e2019020"},{"key":"e_1_2_9_45_1","doi-asserted-by":"publisher","DOI":"10.1208\/s12248-016-9938-6"},{"key":"e_1_2_9_46_1","doi-asserted-by":"publisher","DOI":"10.1007\/s43441-019-00034-0"},{"key":"e_1_2_9_47_1","unstructured":"European Medicines Agency (EMA) Committee for Human Medicinal Products (CHMP). Design of in\u2010use shelf life for solid oral dosage forms in multi\u2010dose containers. Available athttps:\/\/www.ema.europa.eu\/en\/human-regulatory\/research-development\/scientific-guidelines\/qa-quality\/quality-medicines-questions-answers-part-2#design-of-in-use-shelf-life-for-solid-oral-dosage-forms-in-multi-dose-containers-section2018;Accessed 28 October 2019."},{"key":"e_1_2_9_48_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.transci.2018.09.015"},{"key":"e_1_2_9_49_1","doi-asserted-by":"publisher","DOI":"10.1080\/13693780701658280"},{"key":"e_1_2_9_50_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.25.3.426.61603"},{"key":"e_1_2_9_51_1","doi-asserted-by":"publisher","DOI":"10.5694\/mja15.01242"},{"key":"e_1_2_9_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbspin.2018.09.006"},{"key":"e_1_2_9_53_1","unstructured":"European Medicines Agency (EMA) & Heads of Medicines Agencies.Guideline on good pharmacovigilance practices (GVP) Module VI \u2013 Collection management and submission of reports of suspected adverse reactions to medicinal products (Rev 2). Available at:https:\/\/www.ema.europa.eu\/en\/documents\/regulatory-procedural-guideline\/guideline-good-pharmacovigilance-practices-gvp-module-vi-collection-management-submission-reports_en.pdf. 2017;Accessed 1 April 2020."},{"key":"e_1_2_9_54_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40264-015-0264-1"},{"key":"e_1_2_9_55_1","doi-asserted-by":"publisher","DOI":"10.1093\/her\/cyq015"},{"key":"e_1_2_9_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2015.12.026"}],"container-title":["British Journal of Clinical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14392","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bcp.14392","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bcp.14392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,4]],"date-time":"2023-09-04T09:59:13Z","timestamp":1693821553000},"score":1,"resource":{"primary":{"URL":"https:\/\/bpspubs.onlinelibrary.wiley.com\/doi\/10.1111\/bcp.14392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,6,24]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["10.1111\/bcp.14392"],"URL":"https:\/\/doi.org\/10.1111\/bcp.14392","archive":["Portico"],"relation":{},"ISSN":["0306-5251","1365-2125"],"issn-type":[{"value":"0306-5251","type":"print"},{"value":"1365-2125","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,6,24]]}}}